Your browser doesn't support javascript.
loading
Dysregulation of the NRG1/ERBB pathway causes a developmental disorder with gastrointestinal dysmotility in humans.
Le, Thuy-Linh; Galmiche, Louise; Levy, Jonathan; Suwannarat, Pim; Hellebrekers, Debby Mei; Morarach, Khomgrit; Boismoreau, Franck; Theunissen, Tom Ej; Lefebvre, Mathilde; Pelet, Anna; Martinovic, Jelena; Gelot, Antoinette; Guimiot, Fabien; Calleroz, Amanda; Gitiaux, Cyril; Hully, Marie; Goulet, Olivier; Chardot, Christophe; Drunat, Severine; Capri, Yline; Bole-Feysot, Christine; Nitschké, Patrick; Whalen, Sandra; Mouthon, Linda; Babcock, Holly E; Hofstra, Robert; de Coo, Irenaeus Fm; Tabet, Anne-Claude; Molina, Thierry J; Keren, Boris; Brooks, Alice; Smeets, Hubert Jm; Marklund, Ulrika; Gordon, Christopher T; Lyonnet, Stanislas; Amiel, Jeanne; Bondurand, Nadège.
Afiliação
  • Le TL; Laboratory of Embryology and Genetics of Human Malformation, Imagine Institute, INSERM UMR 1163, Université de Paris, Paris, France.
  • Galmiche L; INSERM UMR 1235, TENS, The Enteric Nervous System in Gut and Brain Diseases, IMAD, University of Nantes, Nantes, France.
  • Levy J; Pathology Department, Assistance Publique Hôpitaux de Paris (AP-HP), Necker-Enfants Malades Hospital, Paris, France.
  • Suwannarat P; Genetics Department, Robert Debré Hospital, AP-HP, Paris, France.
  • Hellebrekers DM; Université de Paris, NeuroDiderot, INSERM UMR 1141, Paris, France.
  • Morarach K; Department of Genetics, Mid-Atlantic Permanente Medical Group, Suitland, Maryland, USA.
  • Boismoreau F; Department of Clinical Genetics, Maastricht University Medical Center, Maastricht, Netherlands.
  • Theunissen TE; Division of Molecular Neurobiology, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden.
  • Lefebvre M; Institut de Biologie de l'ENS (IBENS), INSERM, CNRS, École Normale Supérieure, PSL Research University, Paris, France.
  • Pelet A; Department of Genetics and Cell Biology, Maastricht University, Maastricht, Netherlands.
  • Martinovic J; Fetal Pathology Unit, Armand Trousseau Hospital, AP-HP, Paris, France.
  • Gelot A; Laboratory of Embryology and Genetics of Human Malformation, Imagine Institute, INSERM UMR 1163, Université de Paris, Paris, France.
  • Guimiot F; Fetal Pathology Unit, Antoine Béclère Hospital, AP-HP, Paris-Saclay University, Clamart, France.
  • Calleroz A; Neuropathology, Pathology Department, Armand Trousseau Hospital, AP-HP, Paris, France.
  • Gitiaux C; Aix-Marseille University, INMED INSERM UMR1249, Campus de Luminy, Marseille, France.
  • Hully M; Université de Paris, NeuroDiderot, INSERM UMR 1141, Paris, France.
  • Goulet O; Fetal Pathology Unit, Robert Debré Hospital, AP-HP, Paris, France.
  • Chardot C; Pathology and Laboratory Medicine Division, Children's National Hospital, Washington DC, USA.
  • Drunat S; Department of Pediatric Clinical Neurophysiology, Necker-Enfants Malades Hospital, AP-HP, Université de Paris, Paris, France.
  • Capri Y; Department of Pediatric Neurology and Rehabilitation, Necker-Enfants Malades Hospital, AP-HP, Université de Paris, Paris, France.
  • Bole-Feysot C; Department of Pediatric Gastroenterology-Hepatology-Nutrition, Necker-Enfants Malades Hospital, AP-HP, Paris, France.
  • Nitschké P; Department of Pediatric Surgery, Necker-Enfants Malades Hospital, AP-HP, Paris, France.
  • Whalen S; Genetics Department, Robert Debré Hospital, AP-HP, Paris, France.
  • Mouthon L; Université de Paris, NeuroDiderot, INSERM UMR 1141, Paris, France.
  • Babcock HE; Genetics Department, Robert Debré Hospital, AP-HP, Paris, France.
  • Hofstra R; Genomics Core Facility, Imagine Institute-Structure Federative de Recherche Necker, INSERM UMR 1163 and INSERM US24/CNRS UMS 3633, Université de Paris, Paris, France.
  • de Coo IF; Bioinformatics Platform, Imagine Institute, Paris, France.
  • Tabet AC; Clinical Genetics Unit and Reference Center, Anomalies du Développement et Syndromes Malformatifs, AP-HP, Sorbonne University, Armand Trousseau Hospital, Paris, France.
  • Molina TJ; Department of Genetics, La Pitié-Salpêtrière Hospital, AP-HP, Paris, France.
  • Keren B; Children's National Hospital, Rare Disease Institute, Washington, DC, USA.
  • Brooks A; Department of Clinical Genetics, Erasmus Medical Center, Rotterdam, Netherlands.
  • Smeets HJ; Department of Toxicogenomics, Unit Clinical Genomics, Maastricht University, MHeNs School for Mental Health and Neuroscience, Maastricht, Netherlands.
  • Marklund U; Genetics Department, Robert Debré Hospital, AP-HP, Paris, France.
  • Gordon CT; Human Genetics and Cognitive Functions, Institut Pasteur, UMR3571 CNRS, Université de Paris, Paris, France.
  • Lyonnet S; Pathology Department, Assistance Publique Hôpitaux de Paris (AP-HP), Necker-Enfants Malades Hospital, Paris, France.
  • Amiel J; Université de Paris, Imagine Institute, Laboratory of Molecular Mechanisms of Hematological Disorders and Therapeutic Implications, INSERM UMR 1163, Paris, France.
  • Bondurand N; Department of Genetics, La Pitié-Salpêtrière Hospital, AP-HP, Paris, France.
J Clin Invest ; 131(6)2021 03 15.
Article em En | MEDLINE | ID: mdl-33497358
ABSTRACT
Hirschsprung disease (HSCR) is the most frequent developmental anomaly of the enteric nervous system, with an incidence of 1 in 5000 live births. Chronic intestinal pseudo-obstruction (CIPO) is less frequent and classified as neurogenic or myogenic. Isolated HSCR has an oligogenic inheritance with RET as the major disease-causing gene, while CIPO is genetically heterogeneous, caused by mutations in smooth muscle-specific genes. Here, we describe a series of patients with developmental disorders including gastrointestinal dysmotility, and investigate the underlying molecular bases. Trio-exome sequencing led to the identification of biallelic variants in ERBB3 and ERBB2 in 8 individuals variably associating HSCR, CIPO, peripheral neuropathy, and arthrogryposis. Thorough gut histology revealed aganglionosis, hypoganglionosis, and intestinal smooth muscle abnormalities. The cell type-specific ErbB3 and ErbB2 function was further analyzed in mouse single-cell RNA sequencing data and in a conditional ErbB3-deficient mouse model, revealing a primary role for ERBB3 in enteric progenitors. The consequences of the identified variants were evaluated using quantitative real-time PCR (RT-qPCR) on patient-derived fibroblasts or immunoblot assays on Neuro-2a cells overexpressing WT or mutant proteins, revealing either decreased expression or altered phosphorylation of the mutant receptors. Our results demonstrate that dysregulation of ERBB3 or ERBB2 leads to a broad spectrum of developmental anomalies, including intestinal dysmotility.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Pseudo-Obstrução Intestinal / Deficiências do Desenvolvimento / Receptor ErbB-2 / Receptor ErbB-3 / Neuregulina-1 / Mutação Tipo de estudo: Etiology_studies / Prognostic_studies Limite: Adolescent / Animals / Child, preschool / Female / Humans / Male / Newborn / Pregnancy Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Pseudo-Obstrução Intestinal / Deficiências do Desenvolvimento / Receptor ErbB-2 / Receptor ErbB-3 / Neuregulina-1 / Mutação Tipo de estudo: Etiology_studies / Prognostic_studies Limite: Adolescent / Animals / Child, preschool / Female / Humans / Male / Newborn / Pregnancy Idioma: En Ano de publicação: 2021 Tipo de documento: Article